Klivira
Request demo

Automating Plastic Surgery Specialty Drug Prior Auth

Klivira automates plastic surgery specialty drug prior auth, ensuring timely access to high-cost biologics and infused therapies critical for reconstructive, gender-affirming, and complex wound care patients.

Managing prior authorizations for specialty drugs in plastic surgery presents unique challenges, often involving complex medical necessity criteria, benefit-side distinctions, and multi-channel payer submissions. These therapies are vital for patient recovery and outcomes in areas like reconstructive procedures, gender-affirming surgery, and panniculectomy. Klivira's platform is engineered to streamline this intricate workflow, reducing administrative burden and accelerating time-to-medication.

The Challenge of Specialty Drug PA in Plastic Surgery

Plastic surgery practices frequently encounter specialty drug prior authorizations for biologics, biosimilars, and infused agents. These high-cost therapies are integral to complex reconstructive procedures, managing post-surgical complications, or supporting specific patient cohorts such as those undergoing gender-affirming surgery. The process is complicated by the need to determine whether a drug falls under the medical or pharmacy benefit, each with distinct submission channels and documentation requirements, leading to potential delays and benefit-side misclassification.

Navigating Medical vs. Pharmacy Benefit for Specialty Drugs

A core complexity in plastic surgery specialty drug prior auth is accurately identifying the correct benefit pathway. Many high-cost therapies can be covered under either the medical benefit (provider-administered, typically requiring a J-code or HCPCS code) or the pharmacy benefit (patient-administered, routed through a PBM). Klivira's policy engine automates this critical benefit-side determination per drug, per payer, and per patient context, preventing submissions to the wrong channel and reducing administrative rework.

Streamlining Documentation and Payer Connectivity

Effective prior authorization for specialty drugs necessitates comprehensive clinical documentation, including diagnosis, prior-line therapy history, and site-of-care information. Klivira integrates with EMRs to extract relevant data, populating step-therapy documentation from FHIR MedicationRequest and Observation resources. Submissions are routed via appropriate channels, whether through NCPDP SCRIPT ePA for pharmacy benefits, or X12 278 and Da Vinci PAS for medical benefits, ensuring compliance with payer-specific requirements.

Optimizing Site-of-Care and Specialty Pharmacy Handoffs

For medical-benefit specialty drugs, payers often enforce site-of-care policies, steering away from higher-cost settings like hospital outpatient departments. Klivira's platform incorporates site-of-care logic, identifying and flagging policy mismatches before submission. Post-approval, for pharmacy-benefit drugs, Klivira coordinates the handoff to specialty pharmacy partners (e.g., Accredo, CVS Specialty, Optum Specialty), streamlining fulfillment and patient delivery, and reducing time-to-medication.

Addressing Common Failure Modes in Specialty Drug PA

Manual specialty drug PA workflows are prone to specific failure modes, including benefit-side misclassification, inadequate step-therapy documentation, and site-of-care policy violations. Klivira directly addresses these by automating benefit determination, capturing FHIR-based history for step-therapy requirements, and surfacing site-of-care policy alignment. This proactive approach minimizes denials and accelerates patient access to essential therapies for reconstructive and gender-affirming care.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit distinction for specialty drugs in plastic surgery?

Klivira's policy engine automatically determines whether a prescribed specialty drug falls under the medical or pharmacy benefit for a specific payer and patient. This ensures the PA request is routed to the correct channel—NCPDP SCRIPT ePA for pharmacy benefits or X12 278/Da Vinci PAS for medical benefits—preventing common misclassification errors.

Can Klivira integrate with our EMR to pull clinical data for specialty drug PAs?

Yes, Klivira integrates with your EMR to automatically extract necessary clinical documentation. For specialty drug PAs, this includes leveraging FHIR MedicationRequest and Observation resources to populate prior-line therapy history and other critical data required for step-therapy protocols and medical necessity criteria.

How does Klivira help with site-of-care requirements for infused specialty drugs?

Klivira's platform incorporates payer-specific site-of-care logic. For infused specialty drugs often used in reconstructive or complex wound care, it will identify if the proposed site of care aligns with the payer's policy, surfacing any mismatches before submission to prevent denials related to site-of-care violations.

What happens after a specialty drug PA is approved through Klivira?

For pharmacy-benefit specialty drugs, Klivira coordinates the post-approval handoff to the payer's designated specialty pharmacy partner (e.g., Accredo, CVS Specialty, Optum Specialty). This streamlines the fulfillment process, ensuring prescriptions are routed efficiently for patient delivery and reducing overall time-to-medication.

Does Klivira assist with manufacturer copay assistance programs for specialty drugs?

Klivira's workflow identifies the availability of manufacturer copay-assistance programs for specialty drugs and flags specific exclusions, such as those for Medicare patients, to help staff navigate these complex financial considerations. Klivira surfaces this information but does not manage the program enrollment itself.

Related coverage

Other plastic-surgery prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo